Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis

被引：5
|
作者：
Brannigan, Jamie [1 ]
Jones, Joanne L. [2 ]
Stacpoole, Sybil R. L. [1 ,2 ,3 ]
机构：
[1] Univ Cambridge, Jesus Coll, Cambridge CB2 1TN, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Neurol, Cambridge, England
[3] North West Anglia NHS Fdn Trust, Peterborough City Hosp, Dept Neurol, Peterborough, Cambs, England
来源：
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION | 2020年 / 7卷 / 05期
基金：
英国惠康基金;
关键词：
D O I：
10.1212/NXI.0000000000000799
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A 39-year-old right-handed agricultural service engineer developed rapidly evolving severe relapsing-remitting multiple sclerosis (MS). MRI showed multiple T2 hyperintensities throughout his neuroaxis (figure, A). Several lesions showed restricted diffusion, and 2 enhanced. He received steroids for each relapse, making a full recovery (Expanded Disability Status Score [EDSS] 0).
引用
收藏
页数：3
相关论文
共 50 条
  • [41] B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis
    Massey, Jennifer
    Barnett, Yael
    Curnow, Jennifer
    Sutton, Ian
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 100 - 103
  • [42] Low vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosis
    Arnett, Simon
    Sanchez, Sofia Jimenez
    Downing, Jennifer
    Boggild, Mike
    Sun, Jing
    Broadley, Simon A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
  • [43] First reported case of aquired hemophilia A (AHA) as secondary autoimmune disease following alemtuzumab treatment in multiple sclerosis
    Moiola, L.
    Pisa, M.
    D'Angelo, A.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 379 - 380
  • [44] First reported case of Aquired Hemophilia A (AHA) as secondary autoimmune disease following alemtuzumab treatment in multiple sclerosis
    Pisa, M.
    Moiola, L.
    D'angelo, A.
    Martinelli, V.
    Comi, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 404 - 404
  • [45] EMA approves alemtuzumab for the treatment of multiple sclerosis
    Wilkinson, Jonathan
    IMMUNOTHERAPY, 2013, 5 (11) : 1166 - 1166
  • [46] Alemtuzumab: a further option for treatment of multiple sclerosis
    Menge, T.
    Kieseier, B. C.
    Warnke, C.
    Aktas, O.
    Hartung, H. -P.
    NERVENARZT, 2012, 83 (04): : 487 - 501
  • [47] An observational study of alemtuzumab following fingolimod for multiple sclerosis
    Willis, Mark
    Pearson, Owen
    Illes, Zsolt
    Sejbaek, Tobias
    Nielsen, Christian
    Duddy, Martin
    Petheram, Kate
    van Munster, Caspar
    Killestein, Joep
    Malmestrom, Clas
    Tallantyre, Emma
    Robertson, Neil
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2017, 4 (02):
  • [48] Myasthenia gravis following alemtuzumab therapy for multiple sclerosis
    Midaglia, Luciana
    Gratacos, Margarida
    Caronna, Edoardo
    Raguer, Nuria
    Sastre-Garriga, Jaume
    Montalban, Xavier
    Tintore, Mar
    NEUROLOGY, 2018, 91 (13) : 622 - 624
  • [49] Atypical acute motor axonal neuropathy following alemtuzumab treatment in multiple sclerosis patient
    Hradilek, Pavel
    Woznicova, I.
    Slonkova, J.
    Lochmanova, A.
    Zeman, D.
    ACTA NEUROLOGICA BELGICA, 2017, 117 (04) : 965 - 967
  • [50] Multiple sclerosis disease rebound after treatment switch from fingolimod to alemtuzumab
    Willis, M.
    Pearson, O.
    Illes, Z.
    Nielsen, C.
    Sejbaek, T.
    Duddy, M.
    Petheram, K.
    van Munster, C.
    Killestein, J.
    Uitdehaag, B.
    Malmestrom, C.
    Tallantyre, E.
    Robertson, N.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 664 - 665
12345